Literature DB >> 16491954

CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice.

Rui Zheng1, Seiji Yano, Helong Zhang, Emiko Nakataki, Isao Tachibana, Ichiro Kawase, Seiji Hayashi, Saburo Sone.   

Abstract

CD9, a transmembrane protein known as motility-related protein-1, plays a pivotal role in regulating cell adhesion, motility, and proliferation, and has been regarded as an important metastasis-inhibitory factor of various human cancers. However, little information has been obtained regarding the highly metastatic human small-cell lung cancer (SCLC). In the present study, an SCLC cell line (OS3-R5), lacking CD9 expression, was transfected with human CD9 gene to assess the role of CD9 on the metastatic potential of SCLC. CD9 gene transfection into OS3-R5 cells resulted in cell proliferation and motility in vitro. Parental and mock-transfected OS3-R5 cells developed liver metastasis and malignant ascites when they were intravenously inoculated into NK cell-depleted SCID mice. CD9 gene transfection into OS3-R5 cells caused suppression of the liver metastasis and malignant ascites. Immunohistochemical analysis revealed that the number of proliferating tumor cells was significantly fewer in liver lesions produced by CD9 gene-transfected OS3-R5 cells than those produced by parental or mock control OS3-R5 cells. In addition, no detectable levels of CD9 were expressed in metastatic tumor cells in mice bearing CD9 gene-transfected OS3-R5 cells, as well as those in mice bearing parental or mock control OS3-R5 cells. These results suggest that the restored expression of CD9 in SCLC cells may reduce the metastatic spread of SCLC cells via the inhibition of cell proliferation and motility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16491954     DOI: 10.3727/096504005776449699

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  12 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

2.  Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells.

Authors:  Haibo Qiu; Yinsheng Wang
Journal:  J Proteome Res       Date:  2008-04-15       Impact factor: 4.466

3.  Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Jian Huan; Yi Gao; Jing Xu; Wenjiong Sheng; Wei Zhu; Shuyu Zhang; Jianping Cao; Jiang Ji; Liyuan Zhang; Ye Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 4.  Tetraspanins in cell migration.

Authors:  Xupin Jiang; Jiaping Zhang; Yuesheng Huang
Journal:  Cell Adh Migr       Date:  2015-06-19       Impact factor: 3.405

5.  Functional and biochemical studies of CD9 in fibrosarcoma cell line.

Authors:  Shuli Chen; Yingxia Sun; Zhigao Jin; Xianghong Jing
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

Review 6.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

7.  Induction of Smad1 by MT1-MMP contributes to tumor growth.

Authors:  Jaclyn A Freudenberg; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

Review 8.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.

Authors:  Taisei Nakamoto; Yoko Murayama; Kenji Oritani; Claude Boucheix; Eric Rubinstein; Makoto Nishida; Fumie Katsube; Kenji Watabe; Shinichi Kiso; Shusaku Tsutsui; Shinji Tamura; Yasuhisa Shinomura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2009-05-26       Impact factor: 7.527

Review 10.  EpCAM (CD326) finding its role in cancer.

Authors:  P A Baeuerle; O Gires
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.